TLIP Block Versus Retrolaminar Block on Quality of Recovery After Posterior Lumbar Spine Fusion Surgery
TLIP-RLB-QoR
Thoracolumbar Interfascial Plane Block Versus Retrolaminar Block on Quality of Recovery After Posterior Lumbar Spine Fusion Surgery: A Prospective Randomized Controlled Trial
1 other identifier
interventional
70
1 country
1
Brief Summary
This prospective randomized controlled study aims to compare the effects of ultrasound-guided thoracolumbar interfascial plane (TLIP) block versus retrolaminar block on postoperative quality of recovery in patients undergoing posterior lumbar spine fusion surgery. Despite advances in surgical techniques, lumbar spine fusion is associated with significant postoperative pain, which may delay recovery and increase opioid consumption. Recent approaches emphasize multimodal analgesia and opioid-sparing strategies, including regional anesthesia techniques. Interfascial plane blocks, such as TLIP and retrolaminar block, have gained attention due to their safety and effectiveness in targeting the dorsal rami of spinal nerves supplying the posterior spinal structures. The primary outcome of this study is postoperative quality of recovery assessed using the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours. Secondary outcomes include pain scores, opioid consumption, time to ambulation, time to oral intake, and postoperative complications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable postoperative-pain
Started Jun 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 20, 2026
CompletedFirst Posted
Study publicly available on registry
May 27, 2026
CompletedStudy Start
First participant enrolled
June 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
May 27, 2026
May 1, 2026
1 year
April 20, 2026
May 21, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Quality of Recovery-15 (QoR-15) score at 24 hours postoperatively
Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire, a validated 15-item patient-reported outcome measure. Scores range from 0 to 150, with higher scores indicating better postoperative recovery. The primary endpoint is the QoR-15 score at 24 hours after surgery.
24 hours postoperatively
Secondary Outcomes (7)
Pain intensity using Visual Analog Scale (VAS)
30 minutes, 2, 6, 12, and 24 hours postoperatively
Time to first rescue analgesia
Within 24 hours postoperatively
Total nalbuphine consumption
24 hours postoperatively
Time to first ambulation
From end of surgery to first ambulation, assessed up to 48 hours postoperatively
Time to tolerate oral intake
From end of surgery to first tolerated oral intake, assessed up to 48 hours postoperatively
- +2 more secondary outcomes
Study Arms (2)
Thoracolumbar interfascial plane Block Group
EXPERIMENTALPatients will receive ultrasound-guided thoracolumbar interfascial plane block after induction of general anesthesia.
Retrolaminar Block Group
EXPERIMENTALPatients will receive ultrasound-guided retrolaminar block after induction of general anesthesia.
Interventions
Ultrasound-guided injection of local anesthetic posterior to the vertebral lamina at the L3 level.
Ultrasound-guided injection of local anesthetic into the fascial plane between the multifidus and longissimus muscles at the L3 level
Eligibility Criteria
You may qualify if:
- Adult patients aged 18-65 years
- Male and female patients
- Scheduled for elective one- or two-level posterior lumbar instrumented fusion surgery under general anesthesia
- ASA physical status I-III
- BMI \< 35 kg/m²
- Willing to participate and provide informed consent
You may not qualify if:
- Patient refusal to participate
- Coagulopathy or anticoagulant therapy
- Infection at the site of block injection
- Known allergy to local anesthetics
- Chronic opioid use (\>3 months)
- Severe hepatic, renal, or cardiac dysfunction
- Neurological deficits interfering with pain assessment
- Pregnancy or lactation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut University Hospitals
Asyut, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- This is a double-blind study where participants and outcome assessors are blinded to group allocation. The anesthesiologist performing the block is not blinded. Identical dressings are applied to maintain blinding.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Lecturer of Anesthesia, Intensive Care, and Pain Management
Study Record Dates
First Submitted
April 20, 2026
First Posted
May 27, 2026
Study Start
June 1, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
May 27, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share